This editorial highlights that type 2 diabetes is a central pathogenic driver in cardiometabolic HFpEF, emphasizing the need for phenotype-driven management and personalized therapies.
Image: see text
Gorica et al. (Thu,) conducted a editorial in Heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus. This editorial highlights that type 2 diabetes is a central pathogenic driver in cardiometabolic HFpEF, emphasizing the need for phenotype-driven management and personalized therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: